BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2998063)

  • 1. The antiherpes drug (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdU) interferes with formation of N-linked and of O-linked oligosaccharides of the herpes simplex virus type 1 glycoprotein C.
    Olofsson S; Lundström M; Datema R
    Virology; 1985 Nov; 147(1):201-5. PubMed ID: 2998063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Propyl-2-deoxyuridine induced interference with glycosylation in herpes simplex virus infected cells. Nature of PdU-induced modifications of N-linked glycans.
    Olofsson S; Sjöblom I; Hellstrand K; Shugar D; Clairmont C; Hirschberg C
    Arch Virol; 1993; 128(3-4):241-56. PubMed ID: 8382038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of terminal N- and O-glycosylation specific for herpesvirus-infected cells: mechanism of an inhibitor of sugar nucleotide transport across Golgi membranes.
    Olofsson S; Milla M; Hirschberg C; De Clercq E; Datema R
    Virology; 1988 Oct; 166(2):440-50. PubMed ID: 2845656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and related compounds on herpes simplex virus (HSV)-infected cells and HSV thymidine kinase gene-transformed cells.
    Balzarini J; De Clercq E
    Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):379-89. PubMed ID: 2545982
    [No Abstract]   [Full Text] [Related]  

  • 5. Problems associated with the use of (E)-5-(2-bromovinyl)-2'-deoxyuridine for typing herpes simplex virus.
    Swierkosz EM; Arens MQ; Rivetna KA
    J Clin Microbiol; 1985 Mar; 21(3):459-61. PubMed ID: 2984249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herpes simplex virus type 1 that exhibits herpes simplex virus type 2 sensitivity to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    Docherty JJ; Dobson AT; Trimble JJ; Jennings BA
    Intervirology; 1991; 32(5):308-15. PubMed ID: 1657822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2'-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2'-deoxyuridine.
    Balzarini J; Baumgartner H; Bodenteich M; De Clercq E; Griengl H
    J Med Chem; 1989 Aug; 32(8):1861-5. PubMed ID: 2547072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene.
    Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Shimizu K; Seno T
    Mol Pharmacol; 1987 Sep; 32(3):410-6. PubMed ID: 2823092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (E)-5-(2-bromovinyl)-2'-deoxyuridine potentiates ganciclovir-mediated cytotoxicity on herpes simplex virus-thymidine kinase--expressing cells.
    Hamel W; Zirkel D; Mehdorn HM; Westphal M; Israel MA
    Cancer Gene Ther; 2001 May; 8(5):388-96. PubMed ID: 11477459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbocyclic 5-iodo-2'-deoxyuridine (C-IDU) and carbocyclic (E)-5-(2-bromovinyl)-2'-deoxyuridine (C-BVDU) as unique examples of chiral molecules where the two enantiomeric forms are biologically active: interaction of the (+)- and (-)-enantiomers of C-IDU and C-BVDU with the thymidine kinase of herpes simplex virus type 1.
    Balzarini J; De Clercq E; Baumgartner H; Bodenteich M; Griengl H
    Mol Pharmacol; 1990 Mar; 37(3):395-401. PubMed ID: 2156153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on synthesis of herpes simplex virus type 1-specific polypeptides.
    Siegel SA; Otto MJ; De Clercq E; Prusoff WH
    Antimicrob Agents Chemother; 1984 May; 25(5):566-70. PubMed ID: 6329089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.
    Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Seno T
    Mol Pharmacol; 1985 Dec; 28(6):581-7. PubMed ID: 3001499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate potentiates anti-herpes simplex virus type 1 activity of E-5-(2-bromovinyl)-2'-deoxyuridine.
    Pancheva SN
    Acta Virol; 1995 Apr; 39(2):117-9. PubMed ID: 7676937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2'-deoxyuridines and (E)-5-(2-halovinyl)-2'-deoxycytidines.
    Herdewijn P; De Clercq E; Balzarini J; Vanderhaeghe H
    J Med Chem; 1985 May; 28(5):550-5. PubMed ID: 2985782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
    De Clercq E; Desgranges C; Herdewijn P; Sim IS; Jones AS; McLean MJ; Walker RT
    J Med Chem; 1986 Feb; 29(2):213-7. PubMed ID: 3005566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of L cell sublines resistant to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    Shiraki K; Vonka V; De Clercq E; Rapp F
    Intervirology; 1991; 32(4):228-33. PubMed ID: 1650764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation of herpes simplex virus types 1 and 2 by sensitivity to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    Mayo DR
    J Clin Microbiol; 1982 Apr; 15(4):733-6. PubMed ID: 6279696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antiviral spectrum of (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    De Clercq E
    J Antimicrob Chemother; 1984 Aug; 14 Suppl A():85-95. PubMed ID: 6092320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoprotein C of herpes simplex virus type 1: characterization of O-linked oligosaccharides.
    Olofsson S; Sjöblom I; Lundström M; Jeansson S; Lycke E
    J Gen Virol; 1983 Dec; 64 ( Pt 12)():2735-47. PubMed ID: 6319556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different in vitro effects of dual combinations of anti-herpes simplex virus compounds.
    Schinazi RF; Nahmias AJ
    Am J Med; 1982 Jul; 73(1A):40-8. PubMed ID: 6285731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.